[{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"14-C Poziotinib","moa":"EGFR\/HER2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Poziotinib","moa":"Epidermal growth factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0.76000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.76000000000000001,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"||Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||Granulocyte colony stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Unicycive Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"Lanthanum Carbonate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Unicycive Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Spectrum Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.

                          Product Name : Rolvedon

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          July 31, 2023

                          Lead Product(s) : Eflapegrastim

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Assertio Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.

                          Product Name : Rolvedon

                          Product Type : Protein

                          Upfront Cash : $291.0 million

                          April 25, 2023

                          Lead Product(s) : Eflapegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Assertio Therapeutics

                          Deal Size : $757.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting G-CSF which decreases the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

                          Product Name : Rolvedon

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 31, 2023

                          Lead Product(s) : Eflapegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : HM781-36B (poziotinib) is a novel, oral EGFR TKI that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4, which, in turn, leads to the inhibition of the proliferation of tumor cells that overexpress these receptors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 22, 2022

                          Lead Product(s) : Poziotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : HM781-36B (poziotinib) is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 10, 2022

                          Lead Product(s) : Poziotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation,is indicated to decrease the incidence of infection, as manifested by febrile neutropenia.

                          Product Name : Rolvedon

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 09, 2022

                          Lead Product(s) : Eflapegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : HM781-36B (poziotinib) is a novel, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine kinase activity of EGFR as well as HER2 and HER4.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 05, 2022

                          Lead Product(s) : Poziotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : HM781-36B (Poziotinib), novel, oral epidermal growth factor receptor tyrosine kinase inhibitor that inhibits tyrosine kinase activity of EGFR, HER2 and HER4. Importantly this, in turn, leads to inhibition of proliferation of tumor cells that overexpress ...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 26, 2022

                          Lead Product(s) : Poziotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Poziotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 18, 2022

                          Lead Product(s) : Poziotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : In pre-clinical models of cancer, poziotinib, an investigational, orally administered, irreversible tyrosine kinase inhibitor was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to can...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 04, 2022

                          Lead Product(s) : Poziotinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank